Table of Contents
- Trial overview
- Who was studied
- Study phase and design
- What was measured
- How results were checked
- Trial status and size
Trial overview
The source data describe one interventional study of RO7284755 in people with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC).[1] The trial studied RO7284755 together with BCG treatment and was designed to learn whether the approach was safe and whether it showed signs of helping control the cancer.[1]
Who was studied
The target population was people whose bladder cancer had not responded to BCG treatment and who had a high-risk form of NMIBC.[1] This is a bladder cancer that has not grown into the muscle layer, but still has a higher chance of coming back or getting worse.[1]
The study summary also shows that the trial looked for the absence of high-risk NMIBC or progressive disease, which means the researchers were watching for either no visible cancer or no worsening of the cancer.[1]
Study phase and design
This was a Phase 1 interventional trial.[1] Phase 1 studies are early studies that mainly focus on safety, tolerability, and finding a dose that can be used for later testing.[1]
The trial summary says Phase I was used to evaluate the safety and tolerability of RO7284755 in combination with BCG, and to determine the maximum-tolerated dose and/or the recommended dose for extension.[1] In simple terms, this means the researchers wanted to find a dose that people could receive with acceptable side effects before moving further in development.[1]
What was measured
The main Phase I outcomes were adverse events, which are unwanted medical problems that happen during a study, and their severity was graded using the NCI CTCAE system.[1] The trial also measured dose-limiting toxicities (DLTs), meaning side effects serious enough to stop a dose from being used as planned.[1]
Another Phase I goal was to choose the recommended dose for extension (RDE) based on safety results.[1] The Phase II part in Cohort A measured the complete response (CR) rate at 12 months, which means the share of participants with no visible cancer at that time point.[1]
How results were checked
The study used cystoscopy, radiologic imaging, and retrospective central pathology review of cytology and biopsy to assess whether the cancer was still present or had progressed.[1] Cystoscopy is a bladder exam with a thin camera, imaging means scans, and pathology review means checking tissue or cell samples under a microscope.[1]
These checks helped the researchers judge both safety and anti-tumor activity in a structured way.[1]
Trial status and size
The trial is listed as completed and included 23 participants.[1] Based on the source data, this is the only RO7284755 trial provided, so the article focuses on this single completed study.[1]
